bioMérieux S.A. (FRA:EYWN)
Germany · Delayed Price · Currency is EUR 99.80
-1.00 (-0.99%)
At close: Jan 28, 2026
bioMérieux Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 4,122 | 3,980 | 3,675 | 3,589 | 3,376 | 3,118 | |
Revenue Growth (YoY) | 8.28% | 8.30% | 2.38% | 6.31% | 8.27% | 16.58% |
Cost of Revenue | 1,802 | 1,765 | 1,617 | 1,580 | 1,375 | 1,365 |
Gross Profit | 2,319 | 2,215 | 2,057 | 2,009 | 2,001 | 1,754 |
Selling, General & Admin | 1,130 | 1,098 | 1,021 | 954.7 | 815.6 | 789.3 |
Research & Development | 500.1 | 491.5 | 460.1 | 446.6 | 385.8 | 398.8 |
Amortization of Goodwill & Intangibles | - | - | - | - | 30.5 | - |
Other Operating Expenses | -49.9 | -46.9 | -33 | -43.6 | -44.6 | -46.9 |
Operating Expenses | 1,616 | 1,577 | 1,488 | 1,396 | 1,187 | 1,141 |
Operating Income | 703.8 | 637.9 | 569 | 613 | 813.5 | 612.5 |
Interest Expense | -15.4 | -16 | -15.8 | -4.1 | -9.1 | -24.9 |
Interest & Investment Income | 14.9 | 14.4 | 12.5 | 1.2 | 1.7 | 1.5 |
Earnings From Equity Investments | - | - | - | - | -0.7 | -0.2 |
Currency Exchange Gain (Loss) | 2.6 | -4.3 | 4.7 | -1.4 | -4.3 | -5.7 |
Other Non Operating Income (Expenses) | -3.7 | -3.5 | 0.2 | -2.2 | 1.3 | 1.3 |
EBT Excluding Unusual Items | 702.2 | 628.5 | 570.6 | 606.5 | 802.4 | 584.5 |
Merger & Restructuring Charges | -0.3 | -0.3 | -0.3 | -9.6 | -0.9 | - |
Impairment of Goodwill | - | - | -94.9 | -29 | -4.6 | -17.5 |
Gain (Loss) on Sale of Investments | - | - | -3.4 | - | 0.6 | -0.6 |
Gain (Loss) on Sale of Assets | - | - | - | 12.8 | - | - |
Asset Writedown | -194.3 | -48.8 | -34.7 | - | -23.7 | - |
Other Unusual Items | 1.6 | - | - | - | - | -42.2 |
Pretax Income | 509.2 | 579.4 | 437.3 | 580.7 | 773.8 | 524.2 |
Income Tax Expense | 138.4 | 154.3 | 114.5 | 140.1 | 175.6 | 121.5 |
Earnings From Continuing Operations | 370.8 | 425.1 | 322.8 | 440.6 | 598.2 | 402.7 |
Minority Interest in Earnings | 7.1 | 7.1 | 34.8 | 11.8 | 2.9 | 1.7 |
Net Income | 377.9 | 432.2 | 357.6 | 452.4 | 601.1 | 404.4 |
Net Income to Common | 377.9 | 432.2 | 357.6 | 452.4 | 601.1 | 404.4 |
Net Income Growth | -8.12% | 20.86% | -20.95% | -24.74% | 48.64% | 48.24% |
Shares Outstanding (Basic) | 118 | 118 | 118 | 118 | 118 | 118 |
Shares Outstanding (Diluted) | 119 | 119 | 119 | 118 | 119 | 119 |
Shares Change (YoY) | 0.08% | -0.06% | 0.32% | -0.39% | 0.20% | -0.05% |
EPS (Basic) | 3.20 | 3.67 | 3.03 | 3.84 | 5.08 | 3.42 |
EPS (Diluted) | 3.17 | 3.64 | 3.01 | 3.82 | 5.06 | 3.41 |
EPS Growth | -8.63% | 20.93% | -21.20% | -24.51% | 48.39% | 48.26% |
Free Cash Flow | 439.4 | 321.5 | 107.1 | 188.4 | 534.6 | 305.3 |
Free Cash Flow Per Share | 3.70 | 2.71 | 0.90 | 1.59 | 4.50 | 2.57 |
Dividend Per Share | 0.900 | 0.900 | 0.850 | 0.850 | 0.850 | 0.620 |
Dividend Growth | 5.88% | 5.88% | - | - | 37.10% | 226.32% |
Gross Margin | 56.27% | 55.66% | 55.99% | 55.97% | 59.26% | 56.24% |
Operating Margin | 17.08% | 16.03% | 15.48% | 17.08% | 24.09% | 19.64% |
Profit Margin | 9.17% | 10.86% | 9.73% | 12.61% | 17.80% | 12.97% |
Free Cash Flow Margin | 10.66% | 8.08% | 2.92% | 5.25% | 15.83% | 9.79% |
EBITDA | 999.5 | 948.2 | 857.8 | 852.6 | 1,005 | 796.5 |
EBITDA Margin | 24.25% | 23.82% | 23.34% | 23.76% | 29.77% | 25.54% |
D&A For EBITDA | 295.7 | 310.3 | 288.8 | 239.6 | 191.6 | 184 |
EBIT | 703.8 | 637.9 | 569 | 613 | 813.5 | 612.5 |
EBIT Margin | 17.08% | 16.03% | 15.48% | 17.08% | 24.09% | 19.64% |
Effective Tax Rate | 27.18% | 26.63% | 26.18% | 24.13% | 22.69% | 23.18% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.